An Isolated-Intestine Withdrawal Response Was Not Whole-Animal Cannabis Withdrawal

A cannabinoid–opioid study measured withdrawal-like contraction in isolated mouse intestine. That tissue endpoint cannot be described as a person’s psychological or whole-body withdrawal syndrome.

What the preparation measured

Investigators incubated ileum from male mice with morphine or the mixed receptor ligand PR-38. Electrical stimulation measured contractility, and naloxone challenge tested a withdrawal response. PR-38 was an experimental mixed-action compound, not THC or cannabis.

The comparisons supported local interaction

Prior morphine exposure reduced its inhibitory effect on subsequent contractions, consistent with tissue tolerance. PR-38 did not show the same loss. Naloxone produced a response after morphine exposure; CB1 blockade could reveal a response in PR-38-exposed tissue.

The endpoint defines the claim

An organ bath can isolate local receptor interactions while excluding brain circuits, subjective symptoms and normal drug distribution. Its experimental timescale also differs from chronic human use. The findings support screening compounds for gastrointestinal adaptation, but do not establish absence of addiction, clinical withdrawal or constipation. A cannabis-treatment claim would require evidence for the actual compound, exposure route and patient outcome, rather than borrowing a favorable result from this preparation.

Related analysis: Cannabis Tolerance Claims: Questions to Ask Before Relying on Expert Testimony.

Primary research

Critical interactions between opioid and cannabinoid receptors during tolerance and physical dependence development to opioids in the murine gastrointestinal tract: proof of concept. Pharmacological reports : PR (2021). DOI: 10.1007/s43440-021-00291-7.